21 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
in the clinical data and safety package in support of cosibelimab. We look forward to providing additional updates in the second quarter.”
2023 and Recent … about the clinical data package, safety, or labeling for the approvability of cosibelimab. Checkpoint intends to address the feedback in a BLA
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
Manufacturer
FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab
Waltham, MA … in a resubmission.
The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.
“As the only
8-K
EX-1.1
8qc6fnwhcw
21 Sep 20
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-1.1
ilv9z
20 Nov 19
Entry into a Material Definitive Agreement
4:50pm
10-12G/A
EX-10.19
q38iw6vu
19 Aug 16
Registration of securities (amended)
12:00am
10-12G
EX-10
yycqad9wtpqhkbofx
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
c99n4
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
43lxy we6d
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
1h1ij8 td
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
gfs67a
11 Jul 16
Registration of securities
12:00am
10-12G/A
EX-10
f822p
16 May 16
Registration of securities (amended)
12:00am
10-12G
EX-10.7
s9dsjrv4fi3 1vc
24 Mar 16
Registration of securities
12:00am
10-12G
EX-10.8
klmly8sblu
24 Mar 16
Registration of securities
12:00am